Drug Details
| General Information of the Drug (ID: DR3489) | ||||
|---|---|---|---|---|
| Name |
Irinotecan
|
|||
| Synonyms |
Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Colorectal cancer [ICD-11: 2B91] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 10,200 mcgh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1660 mcg/L
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 7 mL/min/kg
Elimination
16.7% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 12 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7548 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.51%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.5 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C33H38N4O6
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
|
|||
| InChI |
1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
|
|||
| InChIKey |
UWKQSNNFCGGAFS-XIFFEERXSA-N
|
|||
| CAS Number |
CAS 97682-44-5
|
|||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Flavopiridol | Dysoxylum binectariferum | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2 phase | ||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | Athymic-NCr-nu male mice (8-10 weeks of age) were inoculated subcutaneously in the flank with minced p21-intact HCT116 cells mixed with Matrigel. | |||||
| Experimental
Result(s) |
CPT-11 induces cell cycle arrest rather than cell death and that flavopiridol, by activating the caspase cascade, cleaves the inhibitors of apoptosis and sensitizes the cells to undergo cell death. | |||||
| β. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CD24 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EPCAM | Molecule Info | |||
| Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Molecule Info | [4] | |
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | DNA replication | Click to Show/Hide | ||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | Click to Show/Hide | ||
| WikiPathways | Integrated Pancreatic Cancer Pathway | Click to Show/Hide | ||
